Poghni A Peri-Okonny1, Colby Ayers2, Naim Maalouf3, Sandeep R Das4, James A de Lemos4, Jarett D Berry2,4, Aslan T Turer4, Ian J Neeland4, Philipp E Scherer5, Wanpen Vongpatanasin1,4. 1. Hypertension Section, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Endocrinology Division, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX, USA. 5. Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract
BACKGROUND: Excess adipose tissue has been implicated in the pathogenesis of insulin resistance and atherosclerosis and is a key risk factor for blood pressure (BP) elevation. However, circulating levels of adiponectin, a protein produced by adipose tissue and widely implicated in the pathogenesis of insulin resistance and atherosclerosis, are inversely proportional to adiposity. The relationship between adiponectin and incident hypertension has not been determined in the general US population. METHODS: Normotensive participants (n = 1233) enrolled in the Dallas Heart Study, a multiethnic, probability-based population sample of Dallas County adults were followed for median of 7 years. Retroperitoneal, intraperitoneal, visceral, and subcutaneous adipose tissue were measured at baseline by magnetic resonance imaging. Liver fat content was measured by 1 H-magnetic resonance spectroscopy. Relative risk regression was used to determine the association of adiponectin with incident hypertension after adjustment for age, race, sex, BMI, smoking, diabetes, baseline systolic BP, total cholesterol, and regional fat depot. RESULTS: Of the 1233 study participants (median age 40 years, 40% black, and 56% women), 391 (32%) had developed hypertension over a median follow-up of 7 years. Adiponectin levels were associated with reduced risk of incident hypertension (RR 0.81, 95% CI [0.68-0.96]) in the fully adjusted model, which included liver fat. Similar results were observed after adjustment for subcutaneous or visceral fat depots when tested individually or simultaneously in the model. CONCLUSION: Our study suggested a protective role of adiponectin against incident hypertension independent of body fat distribution.
BACKGROUND: Excess adipose tissue has been implicated in the pathogenesis of insulin resistance and atherosclerosis and is a key risk factor for blood pressure (BP) elevation. However, circulating levels of adiponectin, a protein produced by adipose tissue and widely implicated in the pathogenesis of insulin resistance and atherosclerosis, are inversely proportional to adiposity. The relationship between adiponectin and incident hypertension has not been determined in the general US population. METHODS: Normotensive participants (n = 1233) enrolled in the Dallas Heart Study, a multiethnic, probability-based population sample of Dallas County adults were followed for median of 7 years. Retroperitoneal, intraperitoneal, visceral, and subcutaneous adipose tissue were measured at baseline by magnetic resonance imaging. Liver fat content was measured by 1 H-magnetic resonance spectroscopy. Relative risk regression was used to determine the association of adiponectin with incident hypertension after adjustment for age, race, sex, BMI, smoking, diabetes, baseline systolic BP, total cholesterol, and regional fat depot. RESULTS: Of the 1233 study participants (median age 40 years, 40% black, and 56% women), 391 (32%) had developed hypertension over a median follow-up of 7 years. Adiponectin levels were associated with reduced risk of incident hypertension (RR 0.81, 95% CI [0.68-0.96]) in the fully adjusted model, which included liver fat. Similar results were observed after adjustment for subcutaneous or visceral fat depots when tested individually or simultaneously in the model. CONCLUSION: Our study suggested a protective role of adiponectin against incident hypertension independent of body fat distribution.
Authors: Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He Journal: Lancet Date: 2005 Jan 15-21 Impact factor: 79.321
Authors: Camilla Asferg; Rasmus Møgelvang; Allan Flyvbjerg; Jan Frystyk; Jan S Jensen; Jacob L Marott; Merete Appleyard; Gorm B Jensen; Jørgen Jeppesen Journal: Am J Hypertens Date: 2009-12-17 Impact factor: 2.689
Authors: Lauren K Meyer; Theodore P Ciaraldi; Robert R Henry; Alan C Wittgrove; Susan A Phillips Journal: Adipocyte Date: 2013-05-07 Impact factor: 4.534
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: S Stojanovic; M Deljanin-Ilic; S Ilic; M Stefanovic; D Petrovic; V Petrovic; M Stojanovic Journal: Hippokratia Date: 2020 Jan-Mar Impact factor: 0.471
Authors: Brian A Bergmark; Christopher P Cannon; William B White; Petr Jarolim; Yuyin Liu; Marc P Bonaca; Faiez Zannad; David A Morrow Journal: Diabetes Obes Metab Date: 2017-03-17 Impact factor: 6.577
Authors: Keith M Diaz; John N Booth; Samantha R Seals; Marwah Abdalla; Patricia M Dubbert; Mario Sims; Joseph A Ladapo; Nicole Redmond; Paul Muntner; Daichi Shimbo Journal: Hypertension Date: 2017-01-30 Impact factor: 10.190
Authors: Arnaud D Kaze; Solomon K Musani; Aurelian Bidulescu; Adolfo Correa; Sherita H Golden; Alain G Bertoni; Justin B Echouffo-Tcheugui Journal: Am J Hypertens Date: 2021-11-20 Impact factor: 3.080